Peak Risk of Recurrence Occurs during the First Two Years after a Pancreatectomy in Patients Receiving Neoadjuvant FOLFIRINOX.

导出 OA

翻译打印收藏纠错

作者： Marie-Sophie,Alfano ^[1] ; Jonathan,Garnier ^[1] ; Anaïs,Palen ^[1] ; Jacques,Ewald ^[1] ; Gilles,Piana ^[2] ; Flora,Poizat ^[3] ; Emmanuel,Mitry ^[4] ; Jean-Robert,Delpero ^[1] ; Olivier,Turrini ^[5]

作者单位： Department of Surgical Oncology, Institut Paoli-Calmettes, 13009 Marseille, France. ^[1] Department of Radiology, Institut Paoli-Calmettes, 13009 Marseille, France. ^[2] Department of Pathology, Institut Paoli-Calmettes, 13009 Marseille, France. ^[3] Department of Oncology, Institut Paoli-Calmettes, 13009 Marseille, France. ^[4] Faculté de Médecine, Aix-Marseille University, 13005 Marseille, France. ^[5]

关键词 FOLFIRINOX borderline follow-up pancreatic adenocarcinoma recurrence survival

DOI 10.3390/cancers15215151

PMID 37958326

发布时间 2023-11-17

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交